Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
Medscape

Pharmacologic Management of Heart Failure with Preserved Ejection Fraction

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...